Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31236475 | 0.85 | MEN1 (0.51) | KMT2AMEN1FAAHCNR2CES2 | |
| SCHEMBL7598259 | 0.85 | MEN1 (0.51) | KMT2AMEN1FAAHCNR2CES2 | |
| SCHEMBL7599431 | 0.82 | EPHX2 (0.48) | KMT2AMEN1FAAHCNR2EPHX2 | |
| SCHEMBL9179949 | 0.81 | KMT2A (0.43) | KMT2AMEN1FAAHCNR2ATM | |
| SCHEMBL4388186 | 0.80 | THRB (0.37) | KMT2AMEN1FAAHCNR2ALDH1A1 | |
| SCHEMBL15144447 | 0.80 | KMT2A (0.42) | KMT2AMEN1FAAHCNR2ATM | |
| SCHEMBL9616774 | 0.80 | KMT2A (0.42) | KMT2AMEN1FAAHCNR2ATM | |
| SCHEMBL9430678 | 0.79 | ELANE (0.43) | KMT2AMEN1FAAHCNR2EPHX2 | |
| SCHEMBL734321 | 0.78 | FAAH (0.43) | KMT2AMEN1FAAHCNR2EPHX2 | |
| SCHEMBL8058782 | 0.78 | FAAH (0.43) | KMT2AMEN1FAAHCNR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1429993-B1 | USES OF IMPROVED POLYMER-SUPPORTED PHOTOSENSITIZERS IN THE GENERATION OF SINGLET OXYGEN | LUMIGEN INC (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-1432640-B1 | POLYMER-SUPPORTED PHOTOSENSITISERS | LUMIGEN INC (US) | 2009-01-14 | — | — | EP | disclosed |
| US-6774249-B2 | CROSSLINKED POLYMER BACKBONE TO WHICH IS BOUND A PLURALITY OF PHOTOSENSITIZER GROUPS AND A PLURALITY OF CATIONIC +NR3 OR PR3+ GROUPS | LUMIGEN, INC. | 2004-08-10 | — | — | US | disclosed |
| US-20030095916-A1 | Uses of improved polymer-supported photosensitizers in the generation of singlet oxygen | LUMIGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6545102-B1 | Polymer-immobilized photosensitizers comprise a cross-linked polymer backbone, a plurality of cationic ammonium or phosphonium groups covalently bound to the polymer backbone and an immobilized photosensitizer. | LUMIGEN, INC. | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095916-A1 | Uses of improved polymer-supported photosensitizers in the generation of singlet oxygen | PPOX, ACP1, LCP1 | KMT2A 1265/4885MEN1 4359/4885FAAH 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.